Cellceutix Adds Brain Cancer to Growing List of Indications for Its Novel Cancer Drug
May 30 2012 - 6:15AM
Marketwired
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a
biopharmaceutical company focused on discovering small molecule
drugs to treat unmet medical conditions, including drug-resistant
cancers, announced that its recent research has shown that its
flagship anticancer compound Kevetrin™ has potent anticancer
activity in malignant glioma (brain tumor).
Results from the Company's latest in vitro research activities
have shown that treatment of glioblastoma cell line (U-87 MG) with
Kevetrin™ reactivates p53. The p53 signaling pathway is a crucial
regulator of cell cycle and apoptosis. Remarkably, the p53
signaling pathway is defective in most, if not all, human tumors.
In U-87 MG, Kevetrin™ activated p53 which induced the expression of
p21 that acts as inhibitor of cell cycle progression. Activated p53
also triggered apoptosis by inducing expression of PUMA.
Glioblastoma joins the growing list of cancer types in which
Kevetrin™ has potent anti-tumor activity, which already includes
prostate, lung, breast, colon, head & neck, squamous cell
carcinoma and a leukemia tumor model.
The Company would also like to inform shareholders that it has
registered for the Rodman & Renshaw 14th Annual Healthcare
Conference to be held at the Waldorf Astoria in New York, NY
September 9 - 11, 2012.
"As the commencement of the clinical trials for Kevetrin™ draws
near, we are aware of the need to inform the broader investment
community of our progress," said Leo Ehrlich, Chief Executive
Officer at Cellceutix. "This will be our first global investment
conference introducing Cellceutix to Institutional Investors,
Venture Capital firms, Industry Executives, Private Equity firms
and more. Barring any setbacks, we believe that the clinical trials
will be well-underway by the Redman & Renshaw Conference. Given
the p53 breakthrough and the recent industry focus on
immunotherapies and T-cells in cancer research, we anticipate that
the attention that we are already receiving will be amplified
considerably as we discuss with large-scale investors how Kevetrin™
has taken immunotherapy and chemotherapy to a whole new level."
About Kevetrin™ As a completely new class
of chemistry in medicine, Kevetrin™ has significant potential to be
a major breakthrough in the treatment of solid tumors. Mechanism of
action studies showed Kevetrin's unique ability to affect both wild
and mutant types of p53 (often referred to as the "Guardian Angel
Gene" or the "Guardian Angel of the Human Genome") and that
Kevetrin strongly induced apoptosis (cell death), characterized by
activation of Caspase 3 and cleavage of PARP. Activation of p53
also induced apoptosis by inducing the expression of p53 target
gene PUMA. p53 is an important tumor suppressor that acts to
restrict proliferation by inducing cell cycle checkpoints,
apoptosis, or cellular senescence. In more than 50 percent of all
human carcinomas, p53 is limited in its anti-tumor activities by
mutations in the protein itself. Currently, there are greater than
10 million people with tumors that contain inactivated p53, while a
similar number have tumors in which the p53 pathway is partially
abrogated by inactivation of other signaling components. This has
left cancer researchers with the grand challenge of searching for
therapies that could restore the protein's protective function,
which Kevetrin appears to be doing the majority of the time.
About Cellceutix Headquartered in Beverly,
Massachusetts, Cellceutix is a publicly traded company under the
symbol "CTIX". It is an emerging bio-pharmaceutical company focused
on the development of its pipeline of compounds targeting areas of
unmet medical need. Our flagship compound, Kevetrin™, is an
anti-cancer drug which has demonstrated the ability in pre-clinical
studies to regulate the p53 pathway and attack cancers which have
proven resistant to today's cancer therapies (drug-resistant
cancers). Cellceutix also owns the rights to seven other drug
compounds, including KM-133, which is in development for psoriasis,
and KM-391 for the treatment of the core symptoms of autism. More
information is available on the Cellceutix web site at
www.cellceutix.com.
Safe Harbor Forward-Looking Statements To the extent that
statements in this press release are not strictly historical,
including statements as to revenue projections, business strategy,
outlook, objectives, future milestones, plans, intentions, goals,
future financial conditions, future collaboration agreements, the
success of the Company's development, events conditioned on
stockholder or other approval, or otherwise as to future events,
such statements are forward-looking, and are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The forward-looking statements contained in this
release are subject to certain risks and uncertainties that could
cause actual results to differ materially from the statements made.
Factors that may impact Cellceutix's success are more fully
disclosed in Cellceutix's most recent public filings with the U.S.
Securities and Exchange Commission.
Cellceutix Corp. Leo Ehrlich (978) 236-8717
Innovation Pharmaceuticals (CE) (USOTC:IPIX)
Historical Stock Chart
From Apr 2024 to May 2024
Innovation Pharmaceuticals (CE) (USOTC:IPIX)
Historical Stock Chart
From May 2023 to May 2024